Knight Therapeutics (TSE:GUD) has released an update.
Knight Therapeutics Inc. has announced a successful financial year, with a 12% increase in annual revenues reaching $328,199 and a significant adjusted EBITDA growth of 11%. Despite a net loss, the company marked several milestones, including multiple regulatory approvals across Latin America, strategic in-licensing of new products, and product launches in various countries.
For further insights into TSE:GUD stock, check out TipRanks’ Stock Analysis page.
